The fund will focus on early-stage life sciences companies working on therapeutics, medical devices and technologies, according to a May 11 NYBC news release.
“This is the first venture fund solely dedicated to advancing innovation in blood and cell-based therapies and technologies,” Christopher Hillyer, MD, president and CEO of New York Blood Center and general partner at NYBC Ventures, said in the release. “NYBC Ventures provides companies more than capital, offering access to world-renowned researchers and their labs, cell manufacturing capacity and source materials.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
